MX2017007638A - Regimen de dosificacion para un agonista selectivo de receptor s1p1. - Google Patents
Regimen de dosificacion para un agonista selectivo de receptor s1p1.Info
- Publication number
- MX2017007638A MX2017007638A MX2017007638A MX2017007638A MX2017007638A MX 2017007638 A MX2017007638 A MX 2017007638A MX 2017007638 A MX2017007638 A MX 2017007638A MX 2017007638 A MX2017007638 A MX 2017007638A MX 2017007638 A MX2017007638 A MX 2017007638A
- Authority
- MX
- Mexico
- Prior art keywords
- dosing regimen
- selective
- receptor agonist
- propylimino
- thiazolidin
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
Abstract
La presente invención se refiere a un régimen de dosificación para (R)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)-benz[Z]iliden]-2-([Z ]- propilimino)-3-o-tolil-tiazolidin-4-ona.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2014077469 | 2014-12-11 | ||
| EP2015058202 | 2015-04-15 | ||
| PCT/EP2015/079208 WO2016091996A1 (en) | 2014-12-11 | 2015-12-10 | Dosing regimen for a selective s1p1 receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017007638A true MX2017007638A (es) | 2017-09-11 |
Family
ID=54843844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007638A MX2017007638A (es) | 2014-12-11 | 2015-12-10 | Regimen de dosificacion para un agonista selectivo de receptor s1p1. |
| MX2020011182A MX2020011182A (es) | 2014-12-11 | 2015-12-10 | Regimen de dosificacion para un agonista selectivo de receptor s1p1. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011182A MX2020011182A (es) | 2014-12-11 | 2015-12-10 | Regimen de dosificacion para un agonista selectivo de receptor s1p1. |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10220023B2 (es) |
| EP (2) | EP4056179A1 (es) |
| JP (1) | JP6244497B1 (es) |
| KR (4) | KR102590068B1 (es) |
| CN (2) | CN106999461A (es) |
| AU (2) | AU2015359346B2 (es) |
| CA (1) | CA2968180C (es) |
| CL (1) | CL2017001457A1 (es) |
| CY (1) | CY1125170T1 (es) |
| DK (1) | DK3256125T3 (es) |
| EA (1) | EA036075B1 (es) |
| ES (1) | ES2909071T3 (es) |
| FR (1) | FR22C1021I2 (es) |
| HR (1) | HRP20220359T8 (es) |
| HU (2) | HUE057865T2 (es) |
| IL (1) | IL252727B (es) |
| LT (2) | LT3256125T (es) |
| MX (2) | MX2017007638A (es) |
| MY (1) | MY188764A (es) |
| NL (1) | NL301174I2 (es) |
| NO (1) | NO2022023I1 (es) |
| PH (1) | PH12017501059A1 (es) |
| PL (1) | PL3256125T3 (es) |
| PT (1) | PT3256125T (es) |
| RS (1) | RS63048B1 (es) |
| SG (1) | SG11201704563RA (es) |
| SI (1) | SI3256125T1 (es) |
| TW (1) | TW201625242A (es) |
| UA (1) | UA122064C2 (es) |
| WO (1) | WO2016091996A1 (es) |
| ZA (1) | ZA201704624B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101980704A (zh) | 2008-03-17 | 2011-02-23 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
| EP4056179A1 (en) | 2014-12-11 | 2022-09-14 | Actelion Pharmaceuticals Ltd | Dosing regimen for ponesimod, a selective s1p1 receptor agonist |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| CA3145269A1 (en) | 2019-07-22 | 2021-01-28 | Michel BURCKLEN | Use of ponesimod for the treatment of multiple sclerosis |
| IL292529A (en) | 2019-10-31 | 2022-06-01 | Idorsia Pharmaceuticals Ltd | Combination of cxcr7 antagonist with s1p1 receptor modulator |
| CA3170688A1 (en) | 2020-03-06 | 2021-09-10 | Actelion Pharmaceuticals Ltd | Methods of slowing brain volume loss |
| AU2022236428A1 (en) | 2021-03-17 | 2023-11-02 | Actelion Pharmaceuticals Ltd | Pharmaceutical dosage system |
| US20230114486A1 (en) | 2021-10-11 | 2023-04-13 | Actelion Pharmaceuticals Ltd | Methods Of Treating Multiple Sclerosis |
| US20230144895A1 (en) | 2021-10-11 | 2023-05-11 | Actelion Pharmaceuticals Ltd | Methods Of Treating Multiple Sclerosis |
| CA3220715A1 (en) | 2021-10-11 | 2023-04-20 | Krista Spiller | Methods of treating multiple sclerosis |
| US11951097B2 (en) * | 2021-10-11 | 2024-04-09 | Vanda Pharmaceuticals Inc. | Methods of treating multiple sclerosis |
| WO2023079079A1 (en) | 2021-11-05 | 2023-05-11 | Actelion Pharmaceuticals Ltd | Methods for treating multiple sclerosis |
| WO2023152290A1 (en) | 2022-02-11 | 2023-08-17 | Actelion Pharmaceuticals Ltd | Methods of slowing an increase in brain ventricular volume |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| KR100783835B1 (ko) | 2003-11-21 | 2007-12-10 | 액테리온 파마슈티칼 리미티드 | 면역억제제로서 5-(벤즈-(ｚ)-일리덴-티아졸리딘-4-원유도체 |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| BRPI0518674A2 (pt) | 2004-11-29 | 2008-12-02 | Novartis Ag | regime de dosagem de um agonista de receptor s1p |
| US7879821B2 (en) | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
| KR101255879B1 (ko) | 2006-11-23 | 2013-04-17 | 액테리온 파마슈티칼 리미티드 | 2-이미노-티아졸리딘-4-원 유도체의 신규한 제조 방법 |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| CN101980704A (zh) * | 2008-03-17 | 2011-02-23 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
| GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| PL3409274T3 (pl) | 2008-12-22 | 2020-06-01 | Novartis Ag | Schemat dawkowania dla agonisty receptora s1p |
| HUE026400T2 (en) | 2008-12-22 | 2016-06-28 | Novartis Ag | Dosage Scheme for S1P Receptor Agonist |
| ES2795105T3 (es) | 2012-08-17 | 2020-11-20 | Actelion Pharmaceuticals Ltd | Proceso para la preparación de (2Z,5Z)-5-(3-cloro-4-((R)-2,3-dihidroxipropoxi)bencilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona y producto intermedio usado en dicho proceso |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| EP4056179A1 (en) * | 2014-12-11 | 2022-09-14 | Actelion Pharmaceuticals Ltd | Dosing regimen for ponesimod, a selective s1p1 receptor agonist |
-
2015
- 2015-12-10 EP EP22152212.1A patent/EP4056179A1/en active Pending
- 2015-12-10 EP EP15807916.0A patent/EP3256125B1/en active Active
- 2015-12-10 RS RS20220283A patent/RS63048B1/sr unknown
- 2015-12-10 MY MYPI2017702097A patent/MY188764A/en unknown
- 2015-12-10 MX MX2017007638A patent/MX2017007638A/es unknown
- 2015-12-10 HR HRP20220359TT patent/HRP20220359T8/hr unknown
- 2015-12-10 CN CN201580067209.2A patent/CN106999461A/zh active Pending
- 2015-12-10 PT PT158079160T patent/PT3256125T/pt unknown
- 2015-12-10 CN CN202310732054.6A patent/CN117137912A/zh active Pending
- 2015-12-10 PL PL15807916T patent/PL3256125T3/pl unknown
- 2015-12-10 LT LTEPPCT/EP2015/079208T patent/LT3256125T/lt unknown
- 2015-12-10 HU HUE15807916A patent/HUE057865T2/hu unknown
- 2015-12-10 UA UAA201707086A patent/UA122064C2/uk unknown
- 2015-12-10 MX MX2020011182A patent/MX2020011182A/es unknown
- 2015-12-10 US US15/534,929 patent/US10220023B2/en active Active
- 2015-12-10 SG SG11201704563RA patent/SG11201704563RA/en unknown
- 2015-12-10 EA EA201791286A patent/EA036075B1/ru unknown
- 2015-12-10 TW TW104141578A patent/TW201625242A/zh unknown
- 2015-12-10 AU AU2015359346A patent/AU2015359346B2/en active Active
- 2015-12-10 KR KR1020217032617A patent/KR102590068B1/ko active IP Right Grant
- 2015-12-10 ES ES15807916T patent/ES2909071T3/es active Active
- 2015-12-10 KR KR1020177018950A patent/KR102427123B1/ko active IP Right Grant
- 2015-12-10 SI SI201531811T patent/SI3256125T1/sl unknown
- 2015-12-10 KR KR1020207002611A patent/KR20200013086A/ko not_active Application Discontinuation
- 2015-12-10 KR KR1020237034975A patent/KR20230147768A/ko not_active Application Discontinuation
- 2015-12-10 CA CA2968180A patent/CA2968180C/en active Active
- 2015-12-10 JP JP2017531167A patent/JP6244497B1/ja active Active
- 2015-12-10 WO PCT/EP2015/079208 patent/WO2016091996A1/en active Application Filing
- 2015-12-10 DK DK15807916.0T patent/DK3256125T3/da active
-
2017
- 2017-06-06 IL IL252727A patent/IL252727B/en active IP Right Grant
- 2017-06-07 PH PH12017501059A patent/PH12017501059A1/en unknown
- 2017-06-08 CL CL2017001457A patent/CL2017001457A1/es unknown
- 2017-07-10 ZA ZA2017/04624A patent/ZA201704624B/en unknown
-
2019
- 2019-01-29 US US16/261,327 patent/US10857134B2/en active Active
-
2020
- 2020-04-22 AU AU2020202684A patent/AU2020202684A1/en not_active Abandoned
- 2020-11-05 US US17/090,756 patent/US11771683B2/en active Active
-
2022
- 2022-04-07 CY CY20221100260T patent/CY1125170T1/el unknown
- 2022-05-09 NL NL301174C patent/NL301174I2/nl unknown
- 2022-05-12 HU HUS2200021C patent/HUS2200021I1/hu unknown
- 2022-05-20 LT LTPA2022505C patent/LTPA2022505I1/lt unknown
- 2022-06-01 FR FR22C1021C patent/FR22C1021I2/fr active Active
- 2022-06-10 NO NO2022023C patent/NO2022023I1/no unknown
- 2022-10-13 US US18/046,492 patent/US20230131600A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501059A1 (en) | Dosing regimen for a selective s1p1 agonist | |
| MA41481B1 (fr) | Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif | |
| HK1257166A1 (zh) | 作為大麻素受體2激動劑的苯基衍生物 | |
| IT201700123930A1 (it) | Macchina riempitrice. | |
| SI3402785T1 (sl) | Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana | |
| EP3303323A4 (en) | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists | |
| SI3402783T1 (sl) | Derivati 3-(karboksietil)-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana | |
| EP3253761A4 (en) | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists | |
| EP3372553A4 (en) | BOTTLE CONVEYOR, BOTTLE GRIPPING MECHANISM, BOTTLE GRIP ASSEMBLY FOR FILLING MACHINE | |
| IT201700038347A1 (it) | Macchina riempitrice. | |
| DK3738900T3 (da) | Container, especially for medicines | |
| GB201817943D0 (en) | Galanin-2 receptor agonists |